Dergiler / Turkish Journal of Hematology / 2001 / Cilt: 18 - Sayı: 3

Activated protein C resistance in polycythemia vera

Sayfa
157–164
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Activated protein C resistance and in some cases its association with Leiden mutation in polycythemia vera may not have a major role in the pathogenesis of thromboembolic complications of polycythemia vera.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Activated protein C resistance is a result of a point mutation in factor V gene (Leiden mutation) and can be identified in approximately 50% of patients with thrombosis, making it an important risk factor for thrombosis.
📊
Temel Bulgular & Veri:We compared patients with polycythemia vera (n: 24) for increased risk of thromboembolism and activated protein C resistance, with the results of patients with chronic myelogenous leukemia (n: 27) and healthy control group (n: 52).
💡
Sonuç & Katkı:Activated protein C resistance and in some cases its association with Leiden mutation in polycythemia vera may not have a major role in the pathogenesis of thromboembolic complications of polycythemia vera.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Activated protein C resistance is a result of a point mutation in factor V gene (Leiden mutation) and can be identified in approximately 50% of patients with thrombosis, making it an important risk factor for thrombosis. The aim of this study is to evaluate the role activated protein C resistance in the hypercoagulable state seen in polycythemia vera. We compared patients with polycythemia vera (n: 24) for increased risk of thromboembolism and activated protein C resistance, with the results of patients with chronic myelogenous leukemia (n: 27) and healthy control group (n: 52). Activated protein C resistance test and factor VIII activity was determined by an aPTT based test. Anticardiolipin antibodies IgG and IgM were also determined by ELISA. Leiden mutation was studied with polymerase chain reaction. Venous thromboses were observed in 12.5% and arterial thromboses in 41.6% of patients with polycythemia vera. Arterial thromboses were recognized in 7.4% of patients with chronic myelogenous leukemia. Activated protein C resistance was identified in 20.8% of patients with polycythemia vera and 14.8% with chronic myelogenous leukemia (versus 1.8% of healthy control subjects). The risk of thrombosis in patients with polycythemia vera was independent from the presence of activated protein C resistance. Leiden mutation was observed in only 1 patient out of 4 patients with chronic myelogenous leukemia who had activated protein C resistance, but not thrombosis. Factor VIII levels of patients with chronic myelogenous leukemia (158% ± 14) were higher than healthy control subjects (99% ± 15) (p< 0.05). Patients with activated protein C resistance in both groups had no seropositivity for anticardiolipin antibodies IgG and IgM. Activated protein C resistance and in some cases its association with Leiden mutation in polycythemia vera may not have a major role in the pathogenesis of thromboembolic complications of polycythemia vera.

🔖

Bu Makaleye Atıf Yap

GÜNAY, A., BUDAK, T., ÜSKENT, N., ÖZTÜRK, A., ÖZBEK, U. (2022). Activated protein C resistance in polycythemia vera. Turkish Journal of Hematology, Cilt: 18 - Sayı: 3, 157–164. https://ajindex.com/articles/607128

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Dahlback B, Carlson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Nat Aca Sci USA 1993;90:1004
  2. Fainoi EM, Franchi F, Asti D, Sacchi E, Bernardi F, Manucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993;70: 1067
  3. Koster T. Leiden Thrombophilia Study: Venous thrombosis due to poor anticoagulant response to activated protein C. Lancet 1993;342:1530
  4. Bauer K. Hypercoagulability: a new cofactor in the protein C anticoagulant pathway. N Engl J Med 1994;330:566
  5. Tuddenham EGD. Thrombophilia: The new factor is old factor V. Lancet 1994;353:1515
  6. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64
  7. Voorberg J, Roelse J, Koopman R. Association of idiopathic venous thromboembolism with single point mutation at arginin of factor V. Lancet 1994;343:1535
  8. William GH. Primary and secondary erythrocytosis. In: Joseph JM (ed). Manual of Clinical Hematology. Little Brown and Company, 1995;70
  9. Brown GE, Griffin HZ. Peripheral arterial disease in polycythemia vera. Arch Intern Med 1930;46:705
  10. Frezzato M, Rugger M, Castaman G, Rodeghiero F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993;78:11
  11. Teofili L, De Stefano V, Leone G, Micalizzi P, Lovino MS, Alfano G, Bizzi B. Hematological causes of venous thrombosis in young people: High incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost 1992;67:297
  12. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C and protein S levels and activated protein C resistanca in polychthemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52:14
  13. Calcelas JA, Garcia AA, Garcia FLJ. High plasma levels of PAI-1 in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 1994;75:513
  14. Carvalho A, Ellman L. Activation of coagulation system in polycythemia vera. Blood 1976;47:669
  15. Grune & Stratton, Berlin NI. Diagnosis and classification of the polycythemias. Semin Haematol 1975; 12:33